6 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival ... #EBM #Honc #Osimertinib ... #NSCLC #Survival ... #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Progression-free Survival ... #EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Rate of Survival and the Risk of Death at 90 Days, According to Subgroup #EBM #PCC
Rate of Survival ... According to Subgroup #EBM ... #PCC #ADRENAL # ... #SepticShock #NEJM
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the
Recurrence-free Survival ... Intention-to-Treat Population #EBM ... #Honc #Nivolumab ... Ipilimumab #Melanoma #NEJM
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
stairs, brisk 4 mph ... neuroexam - Oral ... event, follow ACC ... since elective PCI ... perioperative medical and surgical